Anavex Life Sciences Appoints Three Distinguished Researchers To Scientific Advisory Board

NEW YORK, NY – November 28, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced the appointment of three distinguished…

Anavex Life Sciences Announces Data on 41-Week Treatment of ANAVEX 2-73 for Patients with Alzheimer’s Disease

Investigational Treatment suggests to curb Cognitive and Functional Decline − Full data to be presented at CTAD 2016 − NEW YORK, NY – November 22, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL) today announced a positive 41-week update from its Phase 2a study in mild-to-moderate Alzheimer’s disease (AD) patients for…

Anavex Life Sciences Novel Sigma-1 / Sigma-2 Ligand Shows Encouraging Results as an Analgesic in Animal Models of Neuropathic and Visceral Pain

Preclinical Data for ANAVEX 1066 Presented at Society for Neuroscience Annual Meeting NEW YORK, NY – November 14, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL) today reported encouraging preclinical efficacy for the treatment of neuropathic pain and visceral pain with their novel compound, ANAVEX 1066. The poster titled “Mixed sigma-1…

Anavex Life Sciences Novel Sigma-1 / Sigma-2 Ligand Shows Encouraging Results as an Analgesic in Animal Models of Neuropathic and Visceral Pain

Society for Neuroscience Annual Meeting 2016, San Diego, CA J. Sprouse, N. Rebowe, Y. Darbaky, L. Diop, D. Klamer, C. Missling [trx_button type=”square” style=”global” size=”medium” fullsize=”no” link=”http://anavex.com/wp-content/uploads/Mixed-Sigma-1-Sigma-2-ligands-as-analgesics.pdf” popup=”no”]View Poster[/trx_button]